Companies › TME Pharma
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Olaptesed Pegol (A12) Stromal cell-derived factor 1 inhibitor | CXCL12 | Phase 1 | Glioblastoma | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04121455 | Olaptesed Pegol (A12) | Phase 1 | Glioblastoma | Oncology | Dec 2028 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.